Literature DB >> 10185826

List of drug products that have been withdrawn or removed from the market for reasons of safety or effectiveness--FDA. Proposed rule.

.   

Abstract

The Food and Drug Administration (FDA) is proposing to amend its regulations to include a list of drug products that may not be used for pharmacy compounding pursuant to the exemptions under section 503A of the Federal Food, Drug, and Cosmetic Act (the act) because they have had their approval withdrawn or were removed from the market because the drug product or its components have been found to be unsafe or not effective. The list has been compiled under the new statutory requirements of the Food and Drug Administration Modernization Act of 1997 (Modernization Act).

Mesh:

Year:  1998        PMID: 10185826

Source DB:  PubMed          Journal:  Fed Regist        ISSN: 0097-6326


  6 in total

1.  Azepines and piperidines with dual norepinephrine dopamine uptake inhibition and antidepressant activity.

Authors:  Dean G Brown; Peter R Bernstein; Ye Wu; Rebecca A Urbanek; Christopher W Becker; Scott R Throner; Bruce T Dembofsky; Gary B Steelman; Lois A Lazor; Clay W Scott; Michael W Wood; Steven S Wesolowski; David A Nugiel; Stephanie Koch; Jian Yu; Donald E Pivonka; Shuang Li; Carol Thompson; Anna Zacco; Charles S Elmore; Patricia Schroeder; JianWei Liu; Christopher A Hurley; Stuart Ward; Hazel J Hunt; Karen Williams; Joseph McLaughlin; Valerie Hoesch; Simon Sydserff; Donna Maier; David Aharony
Journal:  ACS Med Chem Lett       Date:  2012-11-12       Impact factor: 4.345

2.  Use of Neo-melubrina, a banned antipyretic drug, in San Diego, California: a survey of patients and providers.

Authors:  L Taylor; S Abarca; B Henry; L Friedman
Journal:  West J Med       Date:  2001-09

3.  Metamizole (dipyrone)-associated agranulocytosis. An analysis of German spontaneous reports 1990-2012.

Authors:  Thomas Stammschulte; Wolf-Dieter Ludwig; Bernd Mühlbauer; Elisabeth Bronder; Ursula Gundert-Remy
Journal:  Eur J Clin Pharmacol       Date:  2015-07-15       Impact factor: 2.953

4.  The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics.

Authors:  Ruili Huang; Noel Southall; Yuhong Wang; Adam Yasgar; Paul Shinn; Ajit Jadhav; Dac-Trung Nguyen; Christopher P Austin
Journal:  Sci Transl Med       Date:  2011-04-27       Impact factor: 17.956

Review 5.  Starch Wars-New Episodes of the Saga. Changes in Regulations on Hydroxyethyl Starch in the European Union.

Authors:  Katja-Nicole Adamik; Ivayla D Yozova
Journal:  Front Vet Sci       Date:  2019-01-18

6.  Potential intravenous drug incompatibilities in a pediatric unit.

Authors:  Karla Dalliane Batista Leal; Ramon Weyler Duarte Leopoldino; Rand Randall Martins; Lourena Mafra Veríssimo
Journal:  Einstein (Sao Paulo)       Date:  2016 Apr-Jun
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.